GleamWall
中文EN

CORT CORCEPT THERAPEUTICS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1088856 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY30.0%
TTM net income YoY52.9%
TTM EPS YoY52.9%
Revenue 3-yr CAGR28.9%
Net income 3-yr CAGR21.1%

Margins

Gross margin98.5%
Operating margin11.5%
Net margin16.8%
FCF margin20.2%
EBITDA margin11.8%

Returns

ROE22.1%
ROA17.5%
ROIC (approx.)17.9%
Asset turnover1.04x

Leverage & solvency

Liabilities / assets19.4%
Debt / equity0.00x
Current ratio3.00x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.22x
Accruals ratio-3.9%
Payout ratio—
Capex / revenue0.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$761.41M$675.04M
Cost of revenue$12.98M$10.88M
Gross profit$748.43M$664.16M
R&D expense$254.91M$246.89M
SG&A expense$448.73M$280.32M
Operating income$44.80M$136.95M
Pretax income$66.46M$161.49M
Income tax-$33.19M$20.28M
Net income$99.65M$141.21M
EBITDA$45.95M$137.75M
EPS (basic)0.951.35
EPS (diluted)0.821.23
Weighted avg. shares (diluted)119.99M113.48M
Balance sheet
Cash & equivalents$120.50M$128.66M
Short-term investments$251.66M$255.67M
Receivables$59.79M$53.98M
Inventory$12.87M$12.41M
Current assets$485.46M$471.60M
PP&E, net$1.89M$2.69M
Total assets$836.65M$840.55M
Current liabilities$166.09M$140.77M
Total liabilities$188.85M$160.96M
Shareholders' equity$647.80M$679.59M
Shares outstanding105.97M105.11M
Cash flow statement
Operating cash flow$142.00M$198.29M
Capital expenditure$211,000$2.17M
Free cash flow$141.78M$196.12M
Investing cash flow$69.76M-$177.60M
Financing cash flow-$220.37M-$28.35M
Depreciation & amortization$1.15M$795,000
Stock-based compensation$84.50M$61.35M
Share buybacks$172.91M$15.66M

Free plan shows the latest 2 periods; Pro shows all 26 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.